CLINICAL STUDY PROTOCOL  
A Phase 1b , Open-label Study of the Safety  and Pharmacokinetics of 
EDG -5506 in Adults with Becker Muscular Dystrophy  
Protocol Number:  EDG -5506-002 
Version  Number:  Amendment 5 (Protocol Version 6) 
Compound : EDG -5506 
Brief Title:  Phase 1b Study  of EDG -5506 in Becker Muscular 
Dystrophy  
Study Phase :   1b 
Sponsor Name:  [CONTACT_732712]: [ADDRESS_1001086]  
Boulder, CO [ZIP_CODE]  
Phone: [PHONE_15235]  
Regulatory Agency Identifier  
Number(s):   IND 148144  
Approval Date:  08-MAR -2023
Confidentiality Statement  
This document and accompanying materials contain confidential information belonging to Edgewise 
Therapeutics. Except as otherwise agreed to in writing, by [CONTACT_732700], you agree to hold 
this information in confidence and not copy or disclose it to others (except where required by [CONTACT_117574]) or use it for unauthorized purposes. In t he event of any actual or suspected breach of this obligation, 
Edgewise Therapeutics must be promptly notified.  
DocuSign Envelope ID: 5DE41D60-1EAD-402F-B856-9D1227B1E269
Edgewise Therapeutics   Protocol EDG -5506 -002 
EDG -5506   Version 6.0 
 
CONFIDENTIAL AND PROPRIETARY  Page 2 of 54   Sponsor Signature [CONTACT_732713] : A Phase 1b , Open -label Study of the Safety  and Pharmacokinetics of EDG -5506 
in Adults with Becker Muscular Dystrophy  
Protocol No .: EDG -[ADDRESS_1001087] Information  
 
 
 
 
  
DocuSign Envelope ID: 5DE41D60-1EAD-402F-B856-9D1227B1E269
09 March 2023

Edgewise Therapeutics  Protocol EDG -5506 -002 
EDG -5506  Version 6.0 
CONFIDENTIAL AND PROPRIETARY  Page 3 of 54 Protocol Amendment Summary of Changes Table  
DOCUMENT HISTORY  
Amendment 5 ( Version  6.0) 08-MAR-2023
Amendment 4 (Version 5.0) 11-OCT -2022
Amendment 3 (Version 4.0)  02-JUN-2022
Amendment 2 (Version 3.0)  03-FEB-2022
Amendment 1 (Version 2.0)  20-DEC -2021
Original Protocol  (Version 1.0)  25-OCT -2021
Amendment 5 (Version 6.0) 
Section # and Name  [CONTACT_9353] 1.3: 
Schedule of Activities  Addition of 3 - and 6 -month 
follow -up blood sample 
collection for those who  
withdraw  prior t o the Month 24 
visit.  To follow the time course of  
biomarker  response  following 
treatment withdrawal  
Section 3: Objectives and 
Endpoints  Inclusion of Efficacy and 
Clinical Outcomes as 
Tertiary/Exploratory 
Objectives  To align with  statistical analysis 
defined in Section 9  
Section  4.3: Justification for 
Dose  
Section 6.1: Study 
Intervention Administered  Dose will be reduced  from 
20 mg to 10 mg starting at 
Visit 21  To determine biomarker and 
functional response at a lower dose  
based on emerging data .  
Section 7.2: Participant 
Discontinuation/Withdrawal 
from the Study  Allow re -enrollment for 
participants who withdraw due 
to non -safety reasons  Those who withdraw for a non-safety 
reason (e.g., for family planning due 
to contraceptive requirement within 
the study) may return at a later date 
(e.g., once able to comply with 
contraceptive requirements again ) 
Global  In addition, minor changes have been made to the text (addition of detail 
and for clarification), consistent with standard practices, which do not 
significantly change the intent of the document.  
DocuSign Envelope ID: 5DE41D60-1EAD-402F-B856-9D1227B1E269

Edgewise Therapeutics   Protocol EDG -5506 -002 
EDG -5506   Version 6.0 
 
CONFIDENTIAL AND PROPRIETARY  Page 4 of 54  Table of Contents  
1. Protocol Summary  ................................ ................................ ................................ .......... 7 
1.1. Synopsis  ................................ ................................ ................................ ............................ 7 
1.2. Schema  ................................ ................................ ................................ .............................. 8 
1.3. Schedule  of Activities  ................................ ................................ ................................ .......9 
2. Introduction  ................................ ................................ ................................ ................... 14 
2.1. Study Rationale  ................................ ................................ ................................ ............... 14 
2.2. Background  ................................ ................................ ................................ ..................... 14 
2.2.1.  Disease Background ................................ ................................ ................................ ........ 14 
2.2.2.  Overview of EDG -5506  ................................ ................................ ................................ ..14 
2.3. Benefit/Risk Assessment  ................................ ................................ ................................ 15 
2.3.1.  Risk Assessment  ................................ ................................ ................................ ............. 15 
2.3.2.  Benefit Assessment  ................................ ................................ ................................ ......... 15 
2.3.3.  Overall Benefit: Risk Conclusion  ................................ ................................ ................... 15 
3. Objectives and Endpoints  ................................ ................................ ............................ 16 
4. Study Design  ................................ ................................ ................................ .................. 18 
4.1. Overall  Design  ................................ ................................ ................................ ................ 18 
4.2. Scientific Rationale for Study Design  ................................ ................................ ............ 18 
4.3. Justification for Dose  ................................ ................................ ................................ ......18 
4.4. End of Study Definition  ................................ ................................ ................................ ..19 
5. Study Population  ................................ ................................ ................................ ........... 20 
5.1. Inclusion Criteria  ................................ ................................ ................................ ............ 20 
5.2. Exclusion Criteria  ................................ ................................ ................................ ........... 20 
5.3. Lifestyle Considerations  ................................ ................................ ................................ .21 
5.4. Screen Failures  ................................ ................................ ................................ ................ 21 
6. Study Intervention(s) and Concomitant Therapy  ................................ ...................... 22 
6.1. Study Intervention Administered  ................................ ................................ .................... 22 
6.1.1.  Administration of EDG -5506  ................................ ................................ ......................... 22 
6.2. Preparation/Handling/Storage/Accountability  ................................ ................................ 22 
6.3. Measures to Minimize Bias: Randomization and Blinding  ................................ ............ 23 
6.4. Study Intervention Compliance  ................................ ................................ ...................... 23 
6.5. Dose Modification  ................................ ................................ ................................ .......... 23 
6.6. Continued Access to Study Intervention after the End of the Study  .............................. 23 
6.7. Treatment of Overdose  ................................ ................................ ................................ ...23 
6.8. Concomitant Therapy  ................................ ................................ ................................ .....24 
7. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal ................................ ................................ ........................ 25 
7.1. Discontinuation of Study Intervention  ................................ ................................ ............ 25 
7.2. Participant Discontinuation/Withdrawal from the Study  ................................ ................ [ADDRESS_1001088] to Follow -up................................ ................................ ................................ ............ 26 
8. Study Assessments and Procedures ................................ ................................ ............. 27 
8.1. Efficacy and Clinical Outcome Assessments  ................................ ................................ .27 
8.1.1.  Functional Assessments  ................................ ................................ ................................ ..27 
DocuSign Envelope ID: 5DE41D60-1EAD-402F-B856-9D1227B1E269

Edgewise Therapeutics   Protocol EDG -5506 -002 
EDG -5506   Version 6.0 
 
CONFIDENTIAL AND PROPRIETARY  Page 5 of 54  8.1.2.  Clinical Outcome Assessments  ................................ ................................ ....................... 28 
8.2. Safety Assessments  ................................ ................................ ................................ ......... 29 
8.2.1. Physical and Neurological Examinations  ................................ ................................ .......29 
8.2.2.  Vital Signs  ................................ ................................ ................................ ....................... 29 
8.2.3.  Clinical Safety Laboratory Assessments  ................................ ................................ ........ 29 
8.2.4.  Electrocardiograms  ................................ ................................ ................................ ......... 30 
8.2.5.  Echocardiograms ................................ ................................ ................................ ............. 30 
8.2.6.  DXA Assessment  ................................ ................................ ................................ ............ 30 
8.2.7.  Spi[INVESTIGATOR_038] ................................ ................................ ................................ ....................... 30 
8.2.8.  Oculofacial Assessments  ................................ ................................ ................................ 30 
8.2.9.  Columbia -Suicide Severity Rating Scale (C -SSRS)  ................................ ....................... 30 
8.3. Adverse Events, Serious Adverse Events, and Other Safety Reporting  ......................... 31 
8.3.1.  Time Period and Frequency for Collecting AE and SAE Information  ........................... 31 
8.3.2.  Method of Detecting AEs and SAEs  ................................ ................................ .............. 31 
8.3.3.  Follow -up of AEs and SAEs  ................................ ................................ ........................... 31 
8.3.4.  Regulatory Reporting Requirements for SAEs  ................................ ............................... 31 
8.3.5.  Pregnancy  ................................ ................................ ................................ ........................ 32 
8.4. Pharmac okinetics  ................................ ................................ ................................ ............ 32 
8.5. Genetics and/or Pharmacogenomics  ................................ ................................ ............... 33 
8.6. Biomarkers  ................................ ................................ ................................ ...................... 33 
8.7. Immunogenicity Assessments ................................ ................................ ......................... 33 
8.8. Medical Resource Utilization and Health Economics  ................................ .................... 33 
9. Statistical Considerations  ................................ ................................ ............................. 34 
9.1. Statistical Hypotheses  ................................ ................................ ................................ .....34 
9.2. Sample Size Determination  ................................ ................................ ............................ 34 
9.3. Analysis Sets  ................................ ................................ ................................ ................... 34 
9.4. Statistical Analyses  ................................ ................................ ................................ ......... 34 
9.4.1.  General Considerations  ................................ ................................ ................................ ...34 
9.4.2.  Safety Analyses  ................................ ................................ ................................ ............... 34 
9.4.3.  Efficacy Endpoints  ................................ ................................ ................................ .......... 35 
9.4.4.  Clinical Outcome Endpoints  ................................ ................................ ........................... 35 
9.4.5.  Biomarkers  ................................ ................................ ................................ ...................... 35 
9.4.6.  Pharmacokinetics  ................................ ................................ ................................ ............ 36 
9.5. Interim Analysis  ................................ ................................ ................................ .............. 36 
10. Supporting Documentation and Operational Considerations  ................................ ..37 
Appendix A  Regulatory, Ethical, and Study Oversight Considerations  ................................ .37 
A.1 Regulatory and Ethical C onsiderations  ................................ ................................ ........... 37 
A.2 Financial Disclosure  ................................ ................................ ................................ ........ 37 
A.3 Informed Consent Process  ................................ ................................ .............................. 37 
A.4 Data Protection ................................ ................................ ................................ ................ 38 
A.5 Data Monitoring Committee  ................................ ................................ ........................... 38 
A.6 Dissemination of Clinical Study Data  ................................ ................................ ............. 39 
A.7 Data Quality Assurance  ................................ ................................ ................................ ..39 
A.8 Source Documents  ................................ ................................ ................................ .......... 39 
A.9 Study and Site Start and Closure  ................................ ................................ .................... 40 
DocuSign Envelope ID: 5DE41D60-1EAD-402F-B856-9D1227B1E269

Edgewise Therapeutics   Protocol EDG -5506 -002 
EDG -5506   Version 6.0 
 
CONFIDENTIAL AND PROPRIETARY  Page 6 of 54  A.10  Publication Policy  ................................ ................................ ................................ ........... 40 
Appendix B  Clinical Laboratory Tests  ................................ ................................ ................... 42 
Appendix C  AEs and SAEs: Definitions and Procedures for Recording, Evaluating, 
Follow -up, and Reporting  ................................ ................................ ............................... 43 
C.1 Definition of AE  ................................ ................................ ................................ ............. 43 
C.2 Definition of SAE  ................................ ................................ ................................ ........... 44 
C.3 Recording and Follow -up of AE and/or SAE  ................................ ................................ .[ADDRESS_1001089] of Tables  
Table  1 Schedule of Activities  ................................ ................................ .......................  10 
Table  2 Objectives and Endpoints  ................................ ................................ ..................  16 
Table  3 Examples of Prohibited Concomitant Medications  ................................ ...........  24 
Table  4 Analysis Sets  ................................ ................................ ................................ ..... 34 
 
DocuSign Envelope ID: 5DE41D60-1EAD-402F-B856-9D1227B1E269

Edgewise Therapeutics   Protocol EDG -5506 -002 
EDG -5506   Version 6.0 
 
CONFIDENTIAL AND PROPRIETARY  Page 8 of 54  Objectives  Endpoints  
− Serum cardiac troponin T   
− Serum NT -proBNP   
− Plasma troponin I tissue -specific isoforms (fast 
skeletal, slow skeletal ) 
− Plasma  SomaScan® proteomics  
• To assess the effect of EDG -5506 on 
functional measures in adult s with BMD  • Change from baseline in:  
− NSAA  
− NSAD  
− 4-stair climb  
− 100-meter timed test  
• To assess the effect of EDG -5506 
treatment on self -reported outcomes in 
adult s with BMD  • Change from baseline in:  
− PROMIS -57 
− ACTIVLIM  
ACTIVLIM = activity limitations for participants with upper and/or lower limb impairments;  BMD = Becker 
muscular dystrophy; C-SSRS  = Columbia Suicide Severity Rating Scale ; ECG = electrocardiogram; FEV 1 = forced 
expi[INVESTIGATOR_3741] 1 second; FVC  = forced vital capacity; NT -proBNP  = N-terminal  proho rmone  brain natriuretic 
peptide ; NSAA = North Star Ambulatory Assessment; NSAD = North Star Assessment for Limb -Girdle Type 
Muscular Dystrophies; PROMIS -57 = Patient -Reported Outcomes Measurement Information System; 
PK = pharmacokinetics; SAE = serious adverse event ; AE = adverse event  
Overall Design : 
This is an open -label, single -center, Phase 1b study to assess the safety  and PK of EDG -5506 in 
adults with BMD. This study will enroll participants who completed (through Day  42) the first -
in-human study, EDG -5506 -001. If necessary, addition al (treatment -naïve) participants  from 
outside the EDG -5506 -001 study may be enrolled to meet  the target sample size . 
Number of Participants:  
Enrollment target is based on approximately 8 evaluable participants .  
Intervention Groups  and Duration : 
As this is an open -label study all participants will receive EDG -5506. EDG -5506 will be 
administered at a dose of 10 mg orally  until Visit 8, a dose of 15  mg to Visit 13, a dose of 20 mg 
to Visit 21, followed by  a dose of 10 mg  to Visit 2 7.  
Data Monitoring Committee:  
An Independent D ata Monitoring Committee  (DMC) is being established to enhance the safety 
of trial participants by [CONTACT_732701].  
1.2. Schema  
The study schema is shown in Figure 1. 
DocuSign Envelope ID: 5DE41D60-1EAD-402F-B856-9D1227B1E269

Edgewise Therapeutics   Protocol EDG -5506 -002 
EDG -5506   Version 6.0 
 
CONFIDENTIAL AND PROPRIETARY  Page 9 of 54  Figure 1 Study Schema  
 
1.3. Schedule  of Activities  
The Schedule of Activities (SoA) is provided in Table  1.  
DocuSign Envelope ID: 5DE41D60-1EAD-402F-B856-9D1227B1E269

Edgewise Therapeutics   Protocol EDG -5506 -002 
EDG -5506   Version 6.0 
 
CONFIDENTIAL AND PROPRIETARY  Page 10 of 54  Table  1 Schedule of Activities  
 Screen  Open -label Treatment Period  CSP Section | 
Appendix  
Visit Identifier  1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19  
 Days  Months   
Study Day  / Month  -1 1 2 8 15 29 43 57 71 3 4 5 6 7 8 9 10 11 12   
Visit Window (Days)  -2 0 0 ±1 ±1 ±3 ±1 ±3 ±3 ±3 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5  
Site visit  a X X X   X  X  X X  X X X  X  X NA 
Telemedicine video call     X X  X  X   X    X  X  NA 
Informed consent  X                   A.3 
Demography  and Medical Hx  X                   NA 
Physical and neuro exam  X     X  X  X X  X  X  X  X 8.2.1  
Weight  X         X         X NA 
Height  X                  X NA 
Vital signs  c X X X    X  X  X X  X X X  X  X 8.2.2  
Hematology /Chemistry d X     X  X  X X  X X X  X  X 8.2.3  
Coagulation  d X         X         X 8.2.3  
Urinalysis  X         X X  X  X  X  X 8.2.3  
Serology e X                   8.2.3  
PK sampling f  X X   X   X   X  X  X X X  X  X 8.4 
Urine PK  X     X    X X         8.4 
Biomarker collection  X     X  X  X X  X X X  X  X 8.6 
SomaScan® collection  X     X  X  X X  X X X    X NA 
Dispensing   X    X  X  X X  X X X  X  X NA 
Dose administration  X → → → → → → → → → → → → → → → → → 6.1.1  
Accountability       X  X  X X  X X X  X  X 6.2 
NSAA and NSAD  X X      X   X  X  X    X [IP_ADDRESS]  
4-stair climb , [ADDRESS_1001090]  X X      X   X  X  X    X [IP_ADDRESS] , [IP_ADDRESS]  
Muscle strength and Hand grip  X X    X  X   X  X  X    X [IP_ADDRESS]  
Pedometer   X    X  X  X X X X X X X X X X [IP_ADDRESS]  
DXA assessment  X                  X 8.2.6  
Cardiac assessment  - Echo  X          X        X 8.2.5 
Spi[INVESTIGATOR_038]  X     X  X   X    X    X 8.2.7  
DocuSign Envelope ID: 5DE41D60-1EAD-402F-B856-9D1227B1E269

Edgewise Therapeutics   Protocol EDG -5506 -002 
EDG -5506   Version 6.0 
 
CONFIDENTIAL AND PROPRIETARY  Page 11 of 54   Screen  Open -label Treatment Period  CSP Section | 
Appendix  
Visit Identifier  1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19  
 Days  Months   
Study Day  / Month  -1 1 2 8 15 29 43 57 71 3 4 5 6 7 8 9 10 11 12   
Visit Window (Days)  -2 0 0 ±1 ±1 ±3 ±1 ±3 ±3 ±3 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5  
12-lead electrocardiogram  X     X  X  X X  X  X  X  X 8.2.4  
C-SSRS   X    X     X    X    X 8.2.9   
ACTIVLIM , PROMIS -57  X      X   X  X  X    X [IP_ADDRESS] , [IP_ADDRESS]  
Contraception check  → → → → → → → → → → → → → → → → → → → NA 
Concomitant medications  → → → → → → → → → → → → → → → → → → → 6.8 
SAE and AE monitoring   → → → → → → → → → → → → → → → → → → → 8.3 
 
 
DocuSign Envelope ID: 5DE41D60-1EAD-402F-B856-9D1227B1E269

Edgewise Therapeutics   Protocol EDG -5506 -002 
EDG -5506   Version 6.0 
 
CONFIDENTIAL AND PROPRIETARY  Page 12 of 54   Open -label Treatment Period  CSP Section | 
Appendix  
Visit Identifier  20 21 22 23 24 25 26 27 F/U g ET 3mi ET 6mi  
Study Monthh 13.5 15 16.5  18 19.5 21 22.5 24/ET b 25    
Visit Window (Days)  ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±5 ±7 ±7  
Site visit    X  X  X  X  X X NA 
Telemedicine video call  X  X  X  X  X   NA 
Physical and neuro exam   X  X  X  X    8.2.1  
Weight         X    NA 
Height         X    NA 
Vital signs    X   X  X  X    8.2.2  
Hematology /Chemistry d  X  X  X  X    8.2.3  
Coagulation  d        X    8.2.3  
PK sampling   X  X   X  X  X  8.4 
Biomarker collection   X  X  X  X  X X 8.6 
SomaScan® collection   X  X  X  X  X X NA 
Dispensing   X  X  X      NA 
Dose administration → → → → → → →     6.1.1  
Accountability   X  X  X  X    6.2 
NSAA and NSAD   X  X  X  X    [IP_ADDRESS]  
4-stair climb , [ADDRESS_1001091]   X  X  X  X    [IP_ADDRESS] , [IP_ADDRESS]  
Muscle strength and Hand grip   X  X  X  X    [IP_ADDRESS]  
DXA assessment         X    8.2.6  
Cardiac assessment - Echo         X    8.2.5  
Spi[INVESTIGATOR_038]     X    X    8.2.7  
12-lead electrocardiogram     X    X    8.2.4  
C-SSRS     X    X    8.2.9   
ACTIVLIM , PROMIS -57  X  X  X  X    [IP_ADDRESS] , [IP_ADDRESS]  
Contraception check  → → → → → → → → →   NA 
Concomitant medications  → → → → → → → → →   6.8 
SAE and AE monitoring   → → → → → → → → →   8.3 
 
 
DocuSign Envelope ID: 5DE41D60-1EAD-402F-B856-9D1227B1E269

Edgewise Therapeutics   Protocol EDG -5506 -002 
EDG -5506   Version 6.0 
 
CONFIDENTIAL AND PROPRIETARY  Page 13 of 54  AE = adverse event ; ACTIVLIM = measure of activity limitations for patients with upper and/or lower limb impairments ; CSP = clinical study protocol; C-SSRS = Columbia Suicide Severity Rating Scale ; D = Day; 
DXA  = dual-energy X -ray absorptiometry ; ET = early  termination ; m = meter; NA = not applicable; NSAA = North Star Ambulatory Assessment ; NSAD  = North Star Assessment for Limb Girdle Type Muscular 
Dystrophies ; PK = pharmacokinetics; P ROMIS -57 = Patient -Reported Outcomes Measurement Information System  – 57 items ; SAE = serious adverse event ; “X” = in-clinic; “→”=continuously  
Screening assessments may be performed over [ADDRESS_1001092] 
timepoint is on Day 2. The dose on Day 2 should be administered only after the 24 hour  timepoint. For treatment experienced, Day 1  is pre -dose only.  
g Based on availability , participants may r oll over to the planned  open -label extension prior to the Month 24 visit after complet ion of the ET visit. They  are not required to perform the safety  
follow -up.  
h Starting  at visit 10,  study months are defined as 30 days . Monthly visit s will be separated by 30 days +/ - the visit window . 
i Laboratory  collection s for participants who withdraw  prior to  the Month 24 visit.  
 
 
 
 
DocuSign Envelope ID: 5DE41D60-1EAD-402F-B856-9D1227B1E269
Edgewise Therapeutics   Protocol EDG -[ADDRESS_1001093] 
skeletal muscle myosin is being developed for the treatment of Becker muscular dystrophy 
(BMD) . 
2.1. Study Rationale  
EDG -[ADDRESS_1001094] muscle fibers , EDG -5506 can potentially limit muscle 
breakdown and disease progression in muscular dystrophies such as Duchenne muscular 
dystrophy ( DMD ) and BMD . This open -label study will evaluate the safety, tolerability, and 
pharmacokinetics (PK) of EDG -[ADDRESS_1001095] -in-
human study, EDG -5506 -001 and if necessary, additional (treatment -naïve) participants from 
outside the EDG -5506 -001 study to meet the target sample size . 
2.2. Background  
2.2.1.  Disease Background  
BMD is an inherited condition that causes progressive weakness and wasting of the skeletal and 
cardiac muscles. Structural impairment of muscle from the genetic truncation of the dystrophin 
protein leads to myofiber membrane stress, hypercontraction , and subsequent degeneration with 
muscle use. Biomarkers of myofiber degeneration can be assessed in vivo with an elevation of 
creatine kinase (CK) and troponin in the blood. Human skeletal muscle consists of both fast (type 
IIa, IIx) and slow (type I) myofibers defined by [CONTACT_732702], a protein integral for mus cle 
contraction. In muscular dystrophy , fast (type II) myofibers appear to be particularly susceptible 
to early myofiber degeneration that ultimately proceeds to irreversible loss of muscle function 
with severe disability and early death  (Webster 1988 ). Preventing hypercontraction of fast 
myofibers and therefore circumventing the loss of dystrophin’s structural function may prevent 
myofiber degeneration and preserve skeletal muscle function in BMD.  
2.2.2.  Overview o f EDG -[ADDRESS_1001096] myofiber (type IIa and IIx) myosin inhibitor 
(half-maximal inhibitory concentration [ IC50] of 0.4 µM) , has been  designed to limit the number 
of fast skeletal myosin heads engaged in hypercontract ion. EDG -[ADDRESS_1001097] slow 
myofiber (type I) myosin (IC 50 >100µM), which is present in both skeletal muscle and the heart. 
It is also inactive against the more distantly -related myosin in smooth muscle.  
Nonclinical studies have shown acute pre vention of ex vivo muscle injury upon treatment with 
EDG -5506. In dystrophic mouse muscle ( mdx), modest force reduction secondary to fast 
myofiber inhibition is coupled to protec t against hypercontraction induced force loss, membrane 
rupture, calcium entry , and myofiber degeneration. Single doses of EDG -5506 reduce circulating 
CK after strength or exercise tolerance tests in mdx mice without reducing performance. In 
chronic dosing studies using mdx mice, EDG -5506 reduce s exercise -induced CK, decreases the 
appearance of fibrosis in the diaphragm and increases grip strength. In the more fibrotic DBA/2 
mdx mouse  (Fukada 2010 ), chronic administration of EDG -5506 reduces fibrosis in multiple 
DocuSign Envelope ID: 5DE41D60-1EAD-402F-B856-9D1227B1E269

Edgewise Therapeutics   Protocol EDG -5506 -002 
EDG -5506   Version 6.0 
 
CONFIDENTIAL AND PROPRIETARY  Page 15 of 54  muscle types including the heart. Finally, in dystrophinopathy dogs, a nonclinical mode l that 
more closely mimics human disease (Kornegay 2017 ), EDG -5506 reversibly  decreases 
circulating CK and increases  physical activity, as measured by a wearable device, in short term 
(2-week ) dosing studies . 
Overall, results from the fi rst-in-human Phase 1 study, EDG -5506 -001, demonstrated that 
EDG -5506 was well tolerated at doses up to 40 mg once daily for 14  days in healthy volunteers 
(n=90) and 20 mg once daily for 14 days in adults with BMD (n=5). In  participants treated with 
EDG -5506, reductions in CK and myoglobin were observed.   
A detailed description of the chemistry, pharmacology, efficacy, and safety of EDG -5506 is 
provided in the Investigator’s Brochure  (IB). 
2.3. Benefit/Risk Assessment  
More detailed information about the known and expected benefits and risks and reasonably 
expected  adverse events  (AEs)  of EDG -[ADDRESS_1001098] that  people diagnosed  with BMD may benefit from treatment with 
EDG -5506, however, clinical benefit has not yet been investigated in humans. Refer to the IB for 
details . 
2.3.3.  Overall Benefit: Risk Co nclusion  
Considering the measures taken to minimize risk to participants in this study, the potential risks 
identified in association with EDG -5506 are justified by [CONTACT_732703].  
DocuSign Envelope ID: 5DE41D60-1EAD-402F-B856-9D1227B1E269

Edgewise Therapeutics   Protocol EDG -5506 -002 
EDG -5506   Version 6.0 
 
CONFIDENTIAL AND PROPRIETARY  Page 17 of 54  ACTIVLIM = activity limitations for participants with upper and/or lower limb impairments ; BMD = Becker 
muscular dystrophy;  C-SSRS = Columbia Suicide Severity Rating Scale;  ECG = electrocardiogram; FEV 1 = forced 
expi[INVESTIGATOR_3741] 1 second; FVC  = forced vital capacity;  NT-proBNP = N -terminal prohormone brain natriuretic  
peptide ; NSAA = North Star Am bulatory Assessment; NSAD = North Star Assessment for Limb -Girdle Type 
Muscular Dystrophies; PROMIS -57 = Patient -Reported Outcomes Measurement Information System ; 
PK = pharmacokinetics; SAE = serious adverse event ; AE = adverse event . 
DocuSign Envelope ID: 5DE41D60-1EAD-402F-B856-9D1227B1E269
Edgewise Therapeutics   Protocol EDG -5506 -002 
EDG -5506   Version 6.0 
 
CONFIDENTIAL AND PROPRIETARY  Page 18 of 54  4. Study Design  
4.1. Overall  Design  
This is an open -label, single -center, Phase 1b study to assess the safety  and PK of EDG -5506 in 
adult s with BMD. This study will enroll participants diagnosed with BMD who completed  
(through Day  42) the first -in-human study, EDG -5506 -001. If necess ary, additional participants 
(treatment naïve) from outside the EDG -5506 -001 study may be enrolled to meet the target 
enrollment of 8 evaluable participants  (see Section 9.2 for details) . 
4.2. Scientific Rationale for Study Design  
Prior to the start of this study, EDG -5506 ha d been administered to a total of 90 healt hy 
volunteers and 5 adults with BMD and demonstrated to be well tolerated at doses administered 
up to 40  mg once  daily for 14  days in healthy volunteers and 20  mg once  daily for 14 days in 
adults with BMD . The half -life of EDG -5506 is estimated to be approximately  18 days in healthy 
volunteers and approximately 7 days in adults with B MD. Pharm acokinetic modeling predicts 
that, in the healthy volunteer population, approximately one half of the steady state  plasma  
concentrations  are reached  after approximately 2 weeks, which was the duration of the 
EDG -5506 -001 multiple dose cohorts. In the  Becker population approximately seventy five 
percent of steady  state concentrations were reached on Day 14 in EDG -5506 -001. This study 
aims to characterize th e PK up to and including steady state , confirm ing the safety and 
tolerability observed at higher doses for 14 days, now in the setting of an extended dosing  period . 
The study has an open -label design and will enroll participants who completed EDG -5506-001, 
which was randomized and placebo -controlled. In addition, to meet target enrollment, treatment -
naïve participants from outside EDG -5506 -001 may be enrolled. Participants will be in clinic on 
Day 1 for initial dosing and assessments. Those participants who were randomized to placebo in 
EDG -5506 -001 and treatment -naïve participants from outside the EDG -5506 -001 study will 
undergo an additional day of on -site dosing to provide additional observation  and PK 
assessments . All participants will continue dosing at home and will be instructed to take 
EDG -5506 at night prior to bedtime.  
4.3. Justification for Dose  
In EDG -5506 -001, EDG -5506 was well tolerated in healthy volunteers at single doses of up to 
90 mg and once -daily doses of 40 mg for 14 days. All treatment emergent AEs were mild 
(Grade  1 based on DA IDS AE G rading) in multiple dose cohorts receiving up to [ADDRESS_1001099] common AEs being dizziness or somnolence.  
Adults with BMD  enrolled in Study  EDG -5506 -001, had an apparent terminal  half-life of 
approximately 7 days , suggesting  approximately 75% of the steady state concentration  was 
reached  after 14 days of dosing .  Therefore, exposures at steady state with a daily dose of 15 mg 
in this study are anticipated to b e similar to  exposures observed in the Study EDG -5506 -001 in 
participants with BMD or healthy adult volunteers , at which exposures EDG -5506 was 
well-tolerated with an acceptable  safety profile . Participants will initially dose at 10 mg  followed 
by 15 mg da ily starting  at Visit 8 and 20  mg starting at Visit 13 . Dosing at  15 mg once -daily 
DocuSign Envelope ID: 5DE41D60-1EAD-402F-B856-9D1227B1E269

Edgewise Therapeutics   Protocol EDG -5506 -002 
EDG -5506   Version 6.0 
 
CONFIDENTIAL AND PROPRIETARY  Page 19 of 54  continues to be well tolerated in all participants, including dosing of up to 3 months . Therefore, 
dose will be increased to 20  mg to further  explore the  safety, PK and effects on biomarker s at 
higher exposures.  Data was also reviewed by [CONTACT_732704] 
20 mg at Visit 13.   
All doses were well tolerated. A near maximal reduction in biomarkers of muscle injury (creatine 
kinase, myoglobin and TN NI2) was seen after treatment with [ADDRESS_1001100] scheduled procedure shown in Table  1 Schedule of Activities ( SoA) for the last participant in 
the study .  
DocuSign Envelope ID: 5DE41D60-1EAD-402F-B856-9D1227B1E269

Edgewise Therapeutics   Protocol EDG -5506 -002 
EDG -5506   Version 6.0 
 
CONFIDENTIAL AND PROPRIETARY  Page 20 of 54  5. Study Population  
Prospective approval of protocol deviations to recruitment and enrollment criteria, also known as 
protocol  waivers or exemptions, is not permitted.  
5.1. Inclusion Criteria  
Participants are eligible to be included in the study only if all the following criteria apply:  
1. Type of Participant and Disease Characteristics  
Participants who have completed Study EDG -[ADDRESS_1001101] meet the following : 
a. Male sex at birth and aged 18 to 55 years inclusive at time of consent . 
b. Documented dystrophin mutation with phenotype consistent with BMD . 
c. Ambulatory at Screening (defined as ability to complete 100 meter [m] timed test, 
with or without assistance ). 
d. Body weight ≥ 50 kg at the Screening visit.  
e. Body mass index (BMI) between 20 and 34 kg/m2 inclusive.  
2. Sex and Contraceptive/Barrier Requirements  
Female sexual partners of male participants must use highly effective contraception 
(<1%  failure rate per year)  through [ADDRESS_1001102] dose.  
3. Informed Consent  
Capable of giving signed informed consent as described in Appendix A, which includes 
compliance with the requirements and restrictions listed in the informed consent form 
(ICF) and in this protocol.  
5.2. Exclusion Criteria   
Participants are excluded from the study if any of the following criteria apply:  
Medical Conditions  
1. Any clinical ly significant changes during or following the completion of Study 
EDG -[ADDRESS_1001103] the potential safety of the participant to receiv e 
EDG -5506.  
2. Cardiac echocardiogram  ejection fraction <45% or [LOCATION_001] Heart Association 
(NYHA ) Class III or Class IV . 
3. Baseline 12 -lead electrocardiogram ( ECG ) that demonstrates clinically relevant 
abnormalities that may affect participant safety or i nterpretation of study results . 
4. Forced vital capacity  (FVC)  predicted < 65% or using daytime (mechanical or 
noninvasive) ventilatory support . 
5. Moderate or  severe renal or hepatic impairment (eGFR <60 mL/min/1.73 m2).  
DocuSign Envelope ID: 5DE41D60-1EAD-402F-B856-9D1227B1E269

Edgewise Therapeutics   Protocol EDG -[ADDRESS_1001104] for hepatitis C antibody  (unless negative  HCV PCR ), hepatitis B surface 
antigen, or  human  immunodeficiency virus (HIV) antibody at screening.  
Prior/Concomitant Therapy  
7. History of substance abuse or dependency.  
8. Receipt of oral corticosteroids for >5 days in the previous 6 months at a dose of >5  mg 
equivalent per day. Lower oral doses or inhaled/intranasal steroids are permitted.  
9. Receiving moderate or strong  cytochrome P450 CYP3A4 inhibitors  or inducers . 
10. Participation in any other investigational drug study  or use of use of an inve stigational 
drug within 30 days or 5 half -lives (whichever is longer) of dosing in the present study.  
Other Exclusions  
11. Participants who are unlikely to comply with the study protocol or, in the opi[INVESTIGATOR_15960], would not be a suitable candida te for participation in the study . 
12. Medical history or o ther medical or psychiatric condition including recent (within the 
past year) or active suicidal ideation/behavior or laboratory  result or  abnormality that 
may increase the risk of study participation or, in the Investigator’s judgment, make the 
participant inappropriate for the study . Includes venous access that would be too 
difficult to facilitate repeated blood sampling.  
5.3. Lifestyle Considerations  
EDG -5506 may cause dizziness or drowsiness and so may impair the mental and/or physical 
ability required for the performance of potentially hazardous tasks. Participants should be 
cautioned about operating hazardous machinery, including auto mobiles, until they are reasonably 
certain that the drug treatment does not affect them adversely. Initial advice is to not drive a 
motor vehicle or undertake potentially dangerous work. This will be reassessed based on 
discretion of the Investigator at th e Day [ADDRESS_1001105] if, at any time, they feel impaired during  the study.  
 
 
 
  
5.4. Screen Failures  
Screen failures are defined as participant s who consent to particip ate in the clinical study  but are 
not subsequently entered in the study . A minimal set of screen failure information is required to 
ensure transparent reporting of screen failure participant s to meet the Consolidated Standards of 
Reporting Trials publishing requirements and to respond to queries from regulatory authorities. 
Minimal information includes demography, screen failure details, eligibility criteria, and any 
serious adverse event  (SAE) . 
Individuals who do not meet the criteria for particip ation in this study may be retested or 
rescreened.  
DocuSign Envelope ID: 5DE41D60-1EAD-402F-B856-9D1227B1E269

Edgewise Therapeutics   Protocol EDG -5506 -002 
EDG -5506   Version 6.0 
 
CONFIDENTIAL AND PROPRIETARY  Page 22 of 54  6. Study Intervention (s) and Concomitant Therapy  
Study intervention is defined as the investigational intervention , EDG -5506, intended to be 
administered to a study participant according to this study protocol.  
6.1. Study Intervention Administered  
Intervention name  [CONTACT_732714] -5506  
Type  Drug  
Dose formulation  Tablet  
Unit dose strengths  2.5 mg  or 10 mg  
Dosage level(s)  10 mg daily  until Visit 8  followed by 15  mg daily  until Visit 13 
followed by 20  mg until Visit 21 followed by 10 mg daily  
Route of administration  Oral 
Use Investigational  
Packaging and labeling  Provided in HDPE containers with  child -resistant  screw caps  
Storage  15ºC to 30 ºC  
HDPE = high density  polyethylene  
6.1.1.  Administration of EDG -[ADDRESS_1001106] 
dose. Participants will continue dosing at home, starting in the evening on Day 3  after travel 
home from the site has been completed . 
6.2. Preparation/Handling/Storage/Accountability  
The Investigator or designee must confirm appropriate temperature conditions have been 
maintained during transit for all study intervention received and any discrepancies are reported 
and resolved before use of t he study intervention.  
Only participants enrolled in the study may receive study intervention and only authorized site 
staff may supply or administer study intervention. All study intervention must be stored in a 
secure, environmentally controlled, and mon itored (manual or automated) area in accordance 
with the labeled storage conditions with access limited to the Investigator and authorized site 
staff.  
DocuSign Envelope ID: 5DE41D60-1EAD-402F-B856-9D1227B1E269
Edgewise Therapeutics   Protocol EDG -5506 -002 
EDG -5506   Version 6.0 
 
CONFIDENTIAL AND PROPRIETARY  Page 23 of 54  The Investigator , institution, or the head of the medical institution (where applicable) is 
responsible f or study intervention accountability, reconciliation, and record maintenance 
(i.e., receipt, reconciliation, and final disposition records).  
Further guidance and information for the final disposition of unused study interventions are 
provided in the Pharma cy Manual.  
6.3. Measures to Minimize Bias: Randomization and Blinding  
This is an open -label study; hence , there will be no randomization or blinding. T he participant 
will be assigned EDG -5506 using interactive response technology (IRT) . The site will contact 
[CONTACT_732705].  
6.4. Study Intervention Compliance  
When participants self -administer study intervention(s) at home, compliance will be assessed at 
each site visit. Compliance will be assessed by [CONTACT_732706] s. Deviation(s) from the 
prescribed dosage regimen will be recorded.  In addition to each site visit, telehealth calls, which 
will occur thro ughout the study as noted in the S oA, will include a compliance check on 
EDG -[ADDRESS_1001107] be 
maintained and reconciled with study intervention and compliance records. Intervention start and 
stop dates, including dates for intervention delays and/or dose reductions will also be recorded.  
6.5. Dose Modification  
Dose modifications will be permitted following discussion with the Medical Monitor.  This may 
include changes to dose or frequency of administration.  
6.6. Continued Access to Study Intervention after the End of the Study  
Following completion of the treatment period,  an open -label extension study may be available  
for participants to continue receiving treat ment with EDG -5506 , pending approval by [CONTACT_732707].  
6.7. Treatment of Overdose  
The Sponsor does not recommend specific treatment for an overdose . 
In the event of an overdose, the Investigator  should : 
• Contact [CONTACT_27465].  
• Evaluate the participant to determine, in consultation with the Medical Monitor, whether 
study intervention should be interrupted or whether the dose should be reduced.  
• Closely monitor the participant for any AE/SAE and laborat ory abnormalities . 
DocuSign Envelope ID: 5DE41D60-1EAD-402F-B856-9D1227B1E269
Edgewise Therapeutics   Protocol EDG -5506 -002 
EDG -5506   Version 6.0 
 
CONFIDENTIAL AND PROPRIETARY  Page 24 of 54  6.8. Concomitant Therapy  
Any medication or vaccine (including over -the-counter or prescription medicines, recreational 
drugs, vitamins, and/or herbal supplements) that the participant is receiving at the time of 
enrollment or receives during the study must be  reviewed by [CONTACT_732708]:  
• Reason for use  
• Dates of administration including start and end dates  
• Dosage information including dose and frequency  
The Medical Monitor should be contact[CONTACT_63193].  
Use of strong or moderate CYP3A4  inhibitors or inducers, and examples, not intended to be 
exhaustive, are listed in Table  3. Potential interactions of EDG -[ADDRESS_1001108].  John’s wort, 
barbiturates, modafinil  Etravirine, phenobarbital, 
primidone  
DocuSign Envelope ID: 5DE41D60-1EAD-402F-B856-9D1227B1E269

Edgewise Therapeutics  Protocol EDG -5506 -002 
EDG -5506  Version 6.0 
CONFIDENTIAL AND PROPRIETARY  Page 25 of 54 7. Discontinuation of Study Intervention and Participant
Discontinuation/Withdrawal
Individual dosing may be stopped until safety information can be reviewed in the even t that:  
•A subject experience an SAE that is considered related to EDG -[ADDRESS_1001109] hepatotoxicity are 
elevated in BMD, the liver specific transaminase glutamate dehydrogenase will be follo wed 
(Schomaker 2020 ).  The following criteria will be used.  
Dosing will be paused for an individual until safety information is reviewed and drug induced 
liver injury is r uled out  in the event that:  
•Total bilirubin > 2.[ADDRESS_1001110], or if baseline bilirubin is > ULN, an increase from baseline
value by [CONTACT_8895] [ADDRESS_1001111]
AND  either  
•GLDH is > 2.[ADDRESS_1001112] (10 U/L)
OR 
•ALT is increased by [CONTACT_732709] 2.[ADDRESS_1001113] bilirubin, GGT, PT/INR, and alkaline phosphatase.  
7.1. Discontinuation of Study Intervention  
In rare instances, it may be necessary for a participant to permanently discontinue study 
intervention. Discontinuation of study intervention does not imply withdrawal from the study.  
If study intervention is permanently discontinued, the participant may remain in the study to be 
evaluated. See the SoA (Table  1) for data to be collected at the time of discontinuation of study 
intervention and follow -up and for any further evaluations that need to be completed.  
7.2. Participant Discontinuation/ Withdrawal f rom the Study  
•A participant may withdraw from the study at any time at his/her own request or may be  
withdrawn at any time at the discretion of the Investigator for safety, behavioral, or  
compliance 
reasons. This is expected to be uncommon.
•At the time of study discontinuation, if possible, an early discontinuation visit should be  
conducted, as shown in the SoA (Table 1). See the SoA for data to be collected at the  
time of study discontinuation and follow-up and for any further 
evaluations that need to 
be completed.
•The participant 
will be permanently discontinued both from the study intervention and  
from the study at that time. However, participants who withdraw for non-safety reasons 
may re-enroll (e.g., for family planning due to contraceptive requirement within the 
study)
DocuSign Envelope ID: 5DE41D60-1EAD-402F-B856-9D1227B1E269

Edgewise Therapeutics  Protocol EDG -5506 -002 
EDG -5506  Version 6.0 
CONFIDENTIAL AND PROPRIETARY  Page 26 of 54 and may return at a later date (e.g. , once able to comply with contraceptive requirements 
again). 
•If the participant  withdraws consent  for disclos ure of future information, the Sponsor
may retain and continue to use any data collected before such a withdrawal of consent .
•If a participant  withdraws from the study, he/she may request destruction of any samples
taken and not tested , and the Investigator  must document this in the site study records .
7.3. Lost to Follow -up 
A participant  will be considered lost to follow -up if he or she repeatedly f ails to return for 
scheduled visits and is unable to be contact[CONTACT_9298].  
The following actions must be taken if a participant  fails to return to the clinic for a required 
study visit:  
•The site must attempt to contact [CONTACT_47995] m issed visit as soon as
possible and counsel the participant  on the importance of maintaining the assigned visit
schedule and ascertain whether or not the participant  wishes to and/or should continue in
the study.
•Before a  participant  is deemed lost to f ollow -up, the Investigator  or designee must make
every effort to regain contact [CONTACT_6635]  (where possible, 3 telephone calls and ,
if necessary , a certified letter to the participant ’s last known mailing address or local
equival ent methods). These contact [CONTACT_13140] ’s
medical record .
Discontinuation of specific sites or of the study as a whole is described in  Appendix  A. 
DocuSign Envelope ID: 5DE41D60-1EAD-402F-B856-9D1227B1E269

Edgewise Therapeutics   Protocol EDG -5506 -002 
EDG -5506   Version 6.0 
 
CONFIDENTIAL AND PROPRIETARY  Page 27 of 54  8. Study Assessments and Procedures  
Study procedures and their timing are summarized in the SoA  (Table  1). Protocol  waiver s or 
exemptions are not permitted . 
Immediate  safety concerns  should be discussed with the Sponsor  immediately upon occurrence 
or awareness to determine if the participant should continue or discontinue study intervention . 
Adherence to the study design requirements, including those specified in the SoA, is essential 
and required for study conduct.  
All screening evaluations must be completed and reviewed to confirm that  potential participant s 
meet all eligibility criteria. The Investigator  will maintain a screening log to record details of all 
participant s screened and  to confirm eligibility or record reasons for sc reening failure, as 
applicable.  
Procedures conducted as part of the participant’s routine clinical management (e.g., blood count)  
and obtained before signing of the ICF may be utilized for screening or baseline purposes 
provided the procedures met the protocol -specified criteria and were performed within the time 
frame defined in the SoA . 
8.1. Efficacy and Clinical Outcome Asses sments  
Planned time  points for all  efficacy  and clinical outcome assessments are p rovided in the SoA  
(Table  1). 
8.1.1.  Functional  Assessments  
The functional assessments are briefly described below. Refer to the Clinical Evaluator  Manual 
for details.   
[IP_ADDRESS].  NSAA and NSAD  
The North Star Ambulatory Assessment (NSAA ) and North Star Assessment for Limb Girdle 
Type Muscular Dystrophies (NSAD ) have substantial overlap, with almost all NSAA 
assessments being included in the NSAD. The NSAD inclu des assessments that are harder than 
the most difficult NSAA assessments and that are easier than the easiest NSAA assessments, and 
therefore  decreases the likelihood of either a ceiling or a floor effect for the NSAA. To maintain 
the integrity of the NSAA, the assessments will be performed as a single sequence following the 
order of the NSAA  so identical assessments will not be repeated.  Assessments that are unique to 
the NSAD, starting with the easiest, will be perform ed after all NSAA assessments are complete.  
NSAA  
The NSAA is a [ADDRESS_1001114] that grades performance of various functional skills from 0 (unable 
to perform), 1 (completes independently but with modifications), and 2 (complete without 
compensation)  (Mazzone 2009 ). The NSAA also includes 2 timed functional tests: rise from 
floor and run [ADDRESS_1001115] and 
other functional outcomes in boys with DMD (Mazzone 2009 ). 
DocuSign Envelope ID: 5DE41D60-1EAD-402F-B856-9D1227B1E269

Edgewise Therapeutics   Protocol EDG -5506 -002 
EDG -5506   Version 6.0 
 
CONFIDENTIAL AND PROPRIETARY  Page 28 of 54  NSAD  
The NSAD is a functional scale specifically designed to measure motor performance in 
individuals with limb-girdle muscular dystrophy  and is being evaluated in  BMD  due to the 
similar limb -girdle pattern of weaknes s (Jacobs 2021 ). The NSAD consists of 29 items that are 
considered clinically relevant items from the adapted NSAA  and the Motor Function Measure 
20 with a maximum score of 54 and higher scores indicat ing higher functional abilities.  
[IP_ADDRESS].  4-Stair Climb  
The 4-stair climb test (with or without the use of handrails) quantifies in seconds the time 
required for a participant to ascend [ADDRESS_1001116] steps. The method the participant uses (e .g., using 
the handrails) to climb the stairs is recorded to understand any change in technique that occurs 
over time, however, at no time is the participant instructed on the preferred method (with or 
without the use of handrails) used to perform this test.  
[IP_ADDRESS].  100-Meter Timed Test  
The participant will be asked to complete 4 laps on a 25 m eter track, for a total of 100 meters 
as quickly  and safely as possible, running if able , and the time recorded in seconds.  
[IP_ADDRESS].  Muscle Strength Testing  and Hand Grip Strength  
Musc le strength testing will include assessment of knee extension and flexion and elbow 
extension and flexion  and hand grip strength . Muscle testing will be performed using a hand -held 
dynamometer. Knee myometry will be performed while the participant is in a sitting position 
with knee and hip flexed at 90 degrees. Elbow myometry will be performed while the participant 
is positioned supi[INVESTIGATOR_732695] 90 degrees.   
[IP_ADDRESS].  Pedometer  
To measure daily activity, participants will wear  a pedomet er daily during waking hours  as listed  
the SoA. The pedometer  will be returned to the site at each visit for data upload and returned  to 
the participant for wear through the open -label treatment period  to Visit 1 9. Data may also be 
collected during  telemedicine video  calls in between site visits . Participants will be instructed to 
document daily step count in the participant  diary .   
8.1.2.  Clinical Outcome Assessments  
[IP_ADDRESS].  ACTIVLIM  
This patient -reported measure of activity limitations is to assess individuals with upper and/or 
lower limb impairments  (ACTIVLIM) , which measures the ability to perform daily activities.  
[IP_ADDRESS].  PROMIS -57 
The Patient -Reported Outcomes Measurement Information System (PROM IS) is a set of 
57 patient -reported measures developed by a National I nstitute of Health and evaluates 
physical, mental, and social health.   
DocuSign Envelope ID: 5DE41D60-1EAD-402F-B856-9D1227B1E269

Edgewise Therapeutics   Protocol EDG -5506 -002 
EDG -5506   Version 6.0 
 
CONFIDENTIAL AND PROPRIETARY  Page 29 of 54  8.2. Safety Assessments  
Planned time points  for all safety assessments are provided in the SoA  (Table  1). 
8.2.1.  Physical and Neurological Examinations  
A physical examination will include head, ears, eyes, nose, mouth, skin, heart and lung, lymph 
nodes, and gastrointestinal  and musculoskeletal  systems.  A neurological examination  will also be 
conducted  to include upper and lower limb tone, power, reflexes and  examination of cranial 
nerves II -XII (excluding ophthalmoscopy).   
Abnormal findings will be further characterized as clinically significant or not clinically 
significant for the purposes of reporting as AEs.  
8.2.2.  Vital Signs  
Supi[INVESTIGATOR_9204] ( BP), pulse rate, respi[INVESTIGATOR_697], and temperature will be measured. 
Unscheduled collection times will be permitted, as necessary, to ensure appropriate collect ion of 
safety data.  
Supi[INVESTIGATOR_732696]’s arm supported at the level of the 
heart and recorded to the nearest mmHg after at least [ADDRESS_1001117]. Whenever possible, the 
same arm (preferably the dominant arm) shoul d be used throughout the study.  
Wherever possible, the same size blood pressure cuff, which has been properly sized and 
calibrated, will be used to measure blood pressure each time. The use of automated devices for 
measuring blood pressure and pulse rate a re acceptable, although, when done manually, pulse 
rate will be measured in the brachial/radial artery for at least [ADDRESS_1001118] 
be filed with the source documents.  
Abnormal labor atory findings associated with the underlying disease are not considered 
clinically significant unless judged by [CONTACT_209485]'s condition.  
All laboratory tests with values considered clinically signif icantly abnormal during participation 
in the study should be repeated until the values return to normal or baseline or are no longer 
considered clinically significant by [CONTACT_209486] .  
If clinically significant values do not return to normal/baseline within a period of time judged 
reasonable by [CONTACT_737] , the etiology should be identified , and the Sponsor  notified . 
All protocol -required laboratory tests, as defined in Appendix  B, must be conducted in 
accordance with the laboratory manual and the SoA  (Table  1). 
If laboratory values from non -protocol specified laboratory tests performed at the institution’s 
local laboratory require a change in participant management or are considered clinically 
DocuSign Envelope ID: 5DE41D60-1EAD-402F-B856-9D1227B1E269

Edgewise Therapeutics   Protocol EDG -5506 -002 
EDG -5506   Version 6.0 
 
CONFIDENTIAL AND PROPRIETARY  Page 30 of 54  significant by [CONTACT_737]  (e.g., SAE or AE or dose modification), then the results must be 
recorded . 
8.2.4.  Electrocardiograms  
Triplicate  12-lead ECG will be obtained using an ECG machine that automatically calculates the 
heart rate and measures PR, QRS, QT, and  QTc intervals. All ECGs should be performed after 
the participant has rested quietly for at least 10 minutes in a supi[INVESTIGATOR_2547].  
At each time point at which triplicate ECG are required, 3 individual ECG tracings should be 
obtained as closely as possible in succession,  but no more than 2  minutes apart.  
8.2.5.  Echocardiograms  
Echocardiographic examinations will be performed by a qualified i ndividual (sonographer) at the 
site to evaluate left -ventricular systolic and diastolic function, geometry, and mass, as well as 
left-atrial and right -ventricular function and geometry via two -dimensional, doppler, and/or 
speckle -tracking imaging technique s. Valvular competence, including presence or absence of 
regurgitation, will be evaluated and quantified, while overall cardiac health will be qualitatively 
evaluated (e.g., presence/absence of pericardiac effusion). Echocardiograms will be read locally 
at the site to satisfy inclusion requirements and ensure the safety of the participants; however, 
examinations may also be stored, reviewed, and/or analyzed centrally.  
8.2.6.  DXA Assessment  
Dual-energy X -ray absorptiometry (DXA ) will collect measures of total lean body mass, fat 
mass, and bone mineral density.  The DXA assessment should be performed consistent with 
clinical practice.  
8.2.7.  Spi[INVESTIGATOR_732697] a calibrated spi[INVESTIGATOR_732698] (FVC%) predicted for the participant.  
The predicted FVC% and the largest FVC will be recorded at each time point. The predicted 
FVC% will be pulled against the third National Health and Nutrition Examination Survey 
(NHANES III) (Centers for Disease 1994 ). 
8.2.8.  Oculofacial Assessments  
Examination of cranial nerves II -XII will be performed as part of the neurological examination at 
the time points specified in the SoA . 
8.2.9.  Columbia -Suicide Seve rity Rating Scale (C -SSRS)  
The C -SSRS is a questionnaire used for suicide assessment  developed by [CONTACT_321339], 
including Columbia University, with National Institute of Mental Health  support. The scale is  
evidence -supported and is part of a national and international public health initiative involving 
the assessment of suicidality . 
DocuSign Envelope ID: 5DE41D60-1EAD-402F-B856-9D1227B1E269

Edgewise Therapeutics   Protocol EDG -5506 -002 
EDG -5506   Version 6.0 
 
CONFIDENTIAL AND PROPRIETARY  Page 31 of 54  8.3. Adverse Events , Serious Adverse Events , and Other Safety 
Reporting  
The definitions of AEs and SAEs  can be found in Appendix C . 
Advers e events  will be reported by [CONTACT_2299] . 
The Investigator  and any qualified designees are responsible for detecting, documenting, and 
recording events that meet the definition of an AE or SAE and remain responsible for following 
up all AEs  (see Section  7). 
The method of recording, evaluating, and assessing causality of AE s and SAE s and the 
procedures for completing and transmitting SAE reports are provide d in Appendix C . 
8.3.1.  Time Period and Frequency for Collecting AE and SAE Information  
All SAEs will be collected from the signing of the ICF until the follow -up visit  at the time points 
specified in the SoA ( Table  1). 
All AEs will be collected from the signing of the ICF  until the follow -up visit at the time points 
specified in the SoA ( Table  1). 
All SAEs will be recorded and reported to the Sponsor  or designee immediately and under no 
circumstance should this exceed 24 hours, as indicated in Appendix C . The Investigator  will 
submit any updated SAE data to the Sponsor  within 24  hours of it being available.  
Investigator s are not obligated to actively seek information on AEs or SAE s after conclusion of 
the study participation . However, if the Investigator  learns of any SAE, including a death, at any 
time after a participant has been discharged from the study, and he/she considers the event to be 
reasonably related to the study intervention or study participation, the Investigator  must promptly 
notify the Sponsor  within 24 hours of awareness . 
8.3.2.  Method of Detecting AEs and SAEs  
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open -ended and 
non-leading verbal questioning of the participant is the preferred method to inquire about 
AE occu rrences .  
 
8.3.3.  Follow -up of AEs and SAEs  
After the initial AE/SAE report, the Investigator  is required to proactively follow each 
participant  at subsequent visits/contacts. All SAEs  will be followed until resolution, stabilization, 
the event is otherwise explained, the participant is lost to follow -up, or until the condition 
becomes chronic in nature  (as defined in Sectio n 7.3). Further information on follow -up 
procedures is provided  in Appendix C . 
8.3.4.  Regulatory Reporting Requirements for SAEs  
• Prompt notificat ion by [CONTACT_184159] 
a study intervention under clinical investigation are met.  
DocuSign Envelope ID: 5DE41D60-1EAD-402F-B856-9D1227B1E269

Edgewise Therapeutics   Protocol EDG -5506 -002 
EDG -5506   Version 6.0 
 
CONFIDENTIAL AND PROPRIETARY  Page 32 of 54  • The Sponsor  has a legal responsibility to notify both the local regulatory authority and 
other regulatory agencies about the safety of a study intervention under clinical 
investigation. The Sponsor  will comply with country -specific regulatory requirements 
relating to  safety reporting to the regulatory authority, Institutional Review Boards 
(IRB)/Independent Ethics Committees (IEC) , and Investigator s. 
• An Investigator  who receives an Investigator  safety report describing a n SAE or other 
specific safety information (e .g., summary or listing of SAEs) from the Sponsor  will 
review Investigator Site Files  and notify the IRB/IEC, if appropriate , according to local 
requirements.  
• Investigator  safety reports must be prepared for suspected unexpected serious adverse 
reactions according to local regulatory requirements and Sponsor  policy and forwarded to 
Investigator s as necessary.  Expedited reporting within 7 days will be made for events 
deemed life threatening or death. For all other serious events , reporting shall occur within 
15 days.  
8.3.5.  Pregnancy  
• Details of all pregnancies in female partners of male participants  will be collected after 
the start of study intervention and until  the time period fo r reporting pregnancies aligns  
with the time period for post -intervention contraception determined in Section  5.1. 
• If a pregnancy is reported, the Investigator  will record pregnancy information on the 
appropriate form and submit it to  the Sponsor  within 24 hours  of learning of the 
pregnancy of the female partner  of the participant (after obtaining the necessary signed 
informed consent from the female partner ). 
• While p regnancy itself is not considered to be an AE or SAE, any pregnancy 
complication or elective termination of a pregnancy for medical reasons will be reported 
as an AE or SAE.  
• Abnormal pregnancy outcomes (e .g., spontaneous abortion, fetal death, stillbirth, 
congenital anomalies, ectopic pregnancy) are considered SAEs  and will be reported as 
such. 
• The pregnant female partner  of the participant  will be followed to determine the outcome 
of the pregnancy. The Investigator  will collect follow -up information on the pregnant 
female partner  and the neonate,  and the information will be forwarded to the Sponsor . 
• Any post -study pregnancy -related SAE considered reasonably related to the study 
intervention by [CONTACT_594911]  8.3.4 . While the Investigator  is not obligated to actively seek this information in 
former study participants ’ pregnant female partner , he or she may learn of an SAE 
through spontaneous reporting.  
8.4. Pharmacokinetics  
Samples will be collected for measurement of concentrations of EDG -5506 and metabolites  of 
EDG -5506  as specified in the SoA  (Table  1).  
DocuSign Envelope ID: 5DE41D60-1EAD-402F-B856-9D1227B1E269

Edgewise Therapeutics   Protocol EDG -5506 -002 
EDG -5506   Version 6.0 
 
CONFIDENTIAL AND PROPRIETARY  Page 33 of 54  8.5. Genetics  and/or Pharmacogenomics  
Genetics are not evaluated in this study.  
8.6. Biomarkers  
• Samples  for biomarker research will be collected from all participants in this study as 
specified in the SoA.  
• Biomarker samples will be used for analysis of fast and slow skeletal troponin I, cardiac 
troponin I, cardiac troponin T, NT -proBNP, myoglobin , and creat ine kinase.  
• In addition, these biomarker samples will be stored and used for  biomarker research 
related to pathophysiology of muscular dystrophies .  
• No samples for genetic, genomic , or RNA analysis will be taken.  
• SomaScan® proteomics analysis will be perfo rmed to identify potential biomarkers and 
include evaluation  of association under exploratory endpoints.  
8.7. Immunogenicity Assessments  
Not applicable.  
8.8. Medical Resource Utilization and Health Economic s 
Medical resource utilization and health economics  parameters are not evaluated in this study.  
DocuSign Envelope ID: 5DE41D60-1EAD-402F-B856-9D1227B1E269
Edgewise Therapeutics   Protocol EDG -5506 -002 
EDG -5506   Version 6.0 
 
CONFIDENTIAL AND PROPRIETARY  Page 35 of 54  overall, b y maximum severity, and by [CONTACT_732710] -5506 . Serio us adverse events will 
also be summarized.  
The change from baseline in the following safety endpoints will be summarized at each 
scheduled assessment time point using descriptive statistics : 
• Safety laboratory parameters  
• Vital signs  
• Physical and neurological examination  
• ECG parameters  
• LVEF as assessed by [CONTACT_732711]  
• Pulmonary function as assessed by [CONTACT_10266] 1, FVC  
• C-SSRS  
9.4.3.  Efficacy Endpoints  
The change from baseline in the following efficacy endpoints will be summarized at each 
scheduled assessment time point using descriptive statistics : 
• NSAA  
• NSAD  
• 4-stair climb  
• 100-meter timed test  
• Muscle strength testing  
9.4.4.  Clinical Outcome  Endpoints  
The change  from baseline in the following efficacy endpoints will be summarized at each 
scheduled assessment time point using descriptive statistics : 
• ACTIVLIM  
• PROMIS -57 
9.4.5.  Biomarkers  
The change from baseline in the following efficacy endpoints will be summarized at eac h 
scheduled assessment time point using descriptive statistics : 
• Serum CK 
• Serum cardiac troponin I  
• Serum myoglobin  
• Serum cardiac troponin T  
• Serum NT -proBNP  
DocuSign Envelope ID: 5DE41D60-1EAD-402F-B856-9D1227B1E269
Edgewise Therapeutics   Protocol EDG -5506 -002 
EDG -5506   Version 6.0 
 
CONFIDENTIAL AND PROPRIETARY  Page 36 of 54  • Plasma troponin I tissue -specific isoforms (fast skeletal, slow skeletal)  
• Plasma SomaScan® proteomics   
9.4.6.  Pharmacokinetics  
Treatment -experienced participants:  Exposures will be summarized using descriptive 
statistics at each time point collected. Additional PK analysis may be done outside of the clinical 
study report ( CSR ). 
Treatment -naïve participants:  For Day  1, standard PK parameters endpoints will be estimated 
and summarized using descriptive statistics based on the PK Evaluable Population.  
Exposures will be summarized using descriptive statistics at each time point collected. 
Additiona l PK analysis may be done outside of the CSR.  
9.5. Interim Analys is 
No formal interim analysis is planned.  
DocuSign Envelope ID: 5DE41D60-1EAD-402F-B856-9D1227B1E269
Edgewise Therapeutics   Protocol EDG -5506 -002 
EDG -5506   Version 6.0 
 
CONFIDENTIAL AND PROPRIETARY  Page 37 of 54  10. Supporting Documentation and Operational Considerations  
Appendix A  Regulatory, Ethical, and Study Oversight Considerations  
A.1 Regulatory and Ethical Cons iderations  
• This study will be conducted in accordance with the protocol and with the following:  
− Applicable International Council for Harmonisation (ICH)  Good Clinical Practice 
(GCP) Guidelines  
− Applicable laws and regulations  
• The protocol, protocol amendmen ts, ICF, IB and other relevant documents (e .g., 
advertisements) must be submitted to an IRB/IEC by [CONTACT_46378]/IEC before the study is initiated.  
• Any amendments to the protocol will require IRB/IEC approval before implementation of 
changes made to the study design, except for changes necessary to eliminate an 
immediate hazard to study participants.   
• Protocols and any substantial amendments to the protocol will require health authority 
approval (per local regulations ) prior to initiation except for changes necessary to 
eliminate an immediate hazard to study participants.  
• The Investigator  will be responsible for the following:  
− Providing written summaries of the status of the study to the IRB/IEC annually or 
more freque ntly in accordance with the requirements, policies, and procedures 
established by [CONTACT_1201]/IEC  
− Notifying the IRB/IEC of SAEs or other significant safety findings as required by 
[CONTACT_1744]/IEC procedures  
− Providing oversight of the conduct of the study at the site a nd adherence to 
requirements of 21 Code of Federal Regulations ( CFR ), ICH guidelines, the IRB/IEC, 
and all other applicable local regulations  
A.2 Financial Disclosure  
Investigators and sub -investigators will provide the Sponsor  with sufficient, accurate fi nancial 
information as requested to allow the Sponsor  to submit complete and accurate financial 
certification or disclosure statements to the appropriate regulatory authorities. Investigators are 
responsible for providing information on financial interests  during  the study and for 1 year after 
completion of the study.  
A.3 Informed Consent Process  
• The Investigator  or his/her representative will explain the nature of the study to the 
participant and answer all questions regarding the study.  
• Participants must be informed that their participation is voluntary. Participants  will be 
required to sign a statement of informed consent that meets the requirements of 
DocuSign Envelope ID: 5DE41D60-1EAD-402F-B856-9D1227B1E269
Edgewise Therapeutics   Protocol EDG -[ADDRESS_1001119] (HIPAA ) requirements, where applicable, and the IRB/IEC or study 
center.  
• The medical record must include a statement that written informed consent was obtained 
before the participant was enrolled in the study and the date the written consent was 
obtained. The au thorized person obtaining the informed consent must also sign the ICF.  
• Participants must be re -consented to the most current version of the ICF(s) during their 
participation in the study.  
• A copy of the ICF(s) must be provided to the participant . 
The ICF wi ll contain a separate section that addresses the use of remaining mandatory samples 
for optional exploratory research. The Investigator or authorized designee will explain to each 
participant the objectives of the exploratory research. Participants will be  told that they are free 
to refuse to participate and may withdraw their consent at any time and for any reason during the 
storage period. A separate signature [CONTACT_22862] a participant's agreement to 
allow any remaining specimens to be us ed for exploratory research. Participants who decline to 
participate in this optional research will not provide this separate signature.  
A.4 Data Protection  
• Participants will be assigned a unique identifier by [CONTACT_1034] . Any participant records 
or datase ts that are transferred to the Sponsor  will contain the identifier only; participant 
names or any information that would make the participant identi fiable will not be 
transferred.  
• The participant must be informed that his/her personal study -related data wi ll be used by 
[CONTACT_14342]. The level of disclosure must 
also b e explained to the participant  who will be required to give consent for their data to 
be used as described in the informed consent   
• The participant m ust be informed that his/her medical records may be examined by 
[CONTACT_13162] , by [CONTACT_6667]/IEC members, and by [CONTACT_9326].  
A.[ADDRESS_1001120] membership, and who should be present 
for decisions to be made, how reviews will be performed, and how discussions will be 
documented.  
DocuSign Envelope ID: 5DE41D60-1EAD-402F-B856-9D1227B1E269
Edgewise Therapeutics   Protocol EDG -5506 -002 
EDG -5506   Version 6.0 
 
CONFIDENTIAL AND PROPRIETARY  Page 39 of 54  A.6 Dissemination of Clinical Study Data  
A description of this clinical study will be available on clinicaltrials.gov  as wi ll the summary of 
the study results when they are available. The clinical study and/or summary of study results may 
also be available on other websites according to the regul ations of the countries in which the 
study is conducted.  
A.7 Data Quality Assurance  
• All participant data relating to the study will be recorded on printed or electronic Case 
Report Forms (CRF /eCRF ) unless transmitted to the Sponsor  or designee electronical ly 
(e.g., laboratory data). The Investigator  is responsible for verifying that data entries are 
accurate and correct by [CONTACT_1189].  
• Guidance on completion of CRFs will be provided in Case Report Completion 
Guidelines.  
• The Investigator  must permit study -related monitoring, audits, IRB/IEC review, and 
regulatory agency inspections and provide direct access to source data documents.  
• Monitoring details describing strategy (e .g., risk -based initiatives in operations and 
quality  such as Risk Management and Mitigation Strategies and Analytical Risk -Based 
Monitoring), methods, responsibilities and requirements, including handling of 
noncompliance issues and monitoring techniques (central, remote, or on -site monitoring) 
are provided  in the Monitoring Plan   
• The Sponsor  or designee is responsible for the data management of this study including 
quality checking of the data.  
• The Sponsor  assumes accountability for actions delegated to other individuals (e .g., 
Contract Research Organizations).  
• Records and documents, including signed ICFs, pertaining to the conduct of this study 
must be retained by [CONTACT_13177] 2 years after study completion unless local 
regulations or institutional policies require a longer retention peri od. No records may be 
destroyed during the retention period without the written approval of the Sponsor. No 
records may be transferred to another location or party without written notification to the 
Sponsor.  
A.8 Source Documents  
• Source documents provide e vidence for the existence of the participant and substantiate 
the integrity of the data collected. Source documents are filed at the Investigator ’s site.  
• Data reported on the CRF or entered in the eCRF that are transcribed from source 
documents must be con sistent with the source documents or the discrepancies must be 
explained. The Investigator  may need to request previous medical records or transfer 
records, depending on the study. Also, current medical records must be available.  
• The Investigator  must main tain accurate documentation (source data) that supports the 
information entered in the CRF.  
DocuSign Envelope ID: 5DE41D60-1EAD-402F-B856-9D1227B1E269
Edgewise Therapeutics   Protocol EDG -5506 -002 
EDG -5506   Version 6.0 
 
CONFIDENTIAL AND PROPRIETARY  Page 40 of 54  • Study monitors will perform ongoing source data verification to confirm that data entered 
into the CRF by [CONTACT_1191], complete, and veri fiable from 
source documents; that the safety and rights of participants are being protected; and that 
the study is being conducted in accordance with the currently approved protocol and any 
other study agreements, ICH GCP, and all applicable regulatory re quirements.  
A.[ADDRESS_1001121] site open  and will be the study s tart date.  
Study/Site Termination  
The Sponsor  or designee reserves the right to close the study site or terminate the study at any 
time for any reason at the sole discretion of the Sponsor . Study sites will be closed upon study 
completion. A study site is considered closed when all required documents and study supplies 
have been collected and a study -site closure visit has been performed.  
The Investigator  may initiate study -site closure at any time, provided there is reasonable cause 
and sufficient notice i s given in advance of the intended termination.  
Reasons for the early closure of a study site by [CONTACT_14345]:  
For study termination:  
• Discontinuation of further study intervention development  
For site termi nation:  
• Failure of the Investigator  to comply with the protocol, the requirements of the IRB/IEC 
or local health authorities, the Sponsor 's procedures, or GCP guidelines  
• Inadequate  or no  recruitment  (evaluated after a reasonable amount of time)  of partici pants 
by [CONTACT_737]  
• Total number of participants included earlier than expected  
If the study is prematurely terminated or suspended, the Sponsor  shall promptly inform the 
Investigator s, the IECs/IRBs, the regulatory authorities, and any contract rese arch 
organization(s) used in the study of the reason for termination or suspension, as specified by [CONTACT_13179]. The Investigator  shall promptly inform the participant  and 
should assure appropriate participant  therapy and/or foll ow-up 
A.[ADDRESS_1001122] proprietary information and to provide comments.  
DocuSign Envelope ID: 5DE41D60-1EAD-402F-B856-9D1227B1E269
Edgewise Therapeutics   Protocol EDG -[ADDRESS_1001123] editorial and ethical practice, the Sponsor  will generally support publication of 
multicente r studies only in their entirety and not as individual site data. In this case, a 
coordinating Investigator  [INVESTIGATOR_12992].  
Authorship will be determined by [CONTACT_27495].   
DocuSign Envelope ID: 5DE41D60-1EAD-402F-B856-9D1227B1E269
Edgewise Therapeutics   Protocol EDG -5506 -002 
EDG -5506   Version 6.0 
 
CONFIDENTIAL AND PROPRIETARY  Page 42 of 54  Appendix B  Clinical Laboratory Tests  
 
Chemistries  
Alanine aminotransferase  
Albumin  
Alkaline phosphatase  
Aspartate aminotransferase  
Bicarbonate  
Blood urea nitrogen  
Calcium  
Chloride  
Cholesterol  
Creatine phosphokinase  
Creatinine  
Cystatin C  
Gamma -glutamyl transferase  
Glucose  
Glutamate dehydrogenase  
Lactate dehydrogenase  
Magnesium Phosphorus  
Potassium  
Sodium  
Total  bilirubin  
(Reflex: Direct, indirect bilirubin)  
Total  protein  
Triglycerides  
Uric acid 
 
Coagulation  
Prothrombin time/Partial  
thromboplastin  time Hematology (CBC)  
Reticulocytes  (%)  
Hematocrit  
Hemoglobin  
Platelet  count  
Red blood cell count   
White  blood cell  count  
White blood cell differentia l 
(Percentage and absolute):  
Basophils  
Eosinophils  
Lymphocytes  
Monocytes  
Neutrophils  
 
Urinalysis  (UA)  
Bilirubin  
Color  and appearance   
Glucose  
 Ketones  
Leukocytes  
Microscopi[INVESTIGATOR_19529] (includes RBC and  
WBC)  
Nitrite   
Occult blood  
pH 
Protein   
Specific 
gravity  
Urobilinogen  Biomarkers  
Proteomics platform assessment  
(SomaScan®  Assay)  
Troponin  I (cardiac,  slow skeletal,  and 
fast skeletal)   
Myoglobin, and CK  
Cardiac  Troponin 
T 
NT-proBNP  
 
Other Tests  (Participants  from  
outside EDG -5506 -001 only) :  
 HBsAg   
HCVAb  (reflex if positive HCV RNA)  
HIVAb  
 
CBC = c omplete blood count; CK = creatine kinase;  HBsAg = hepatitis B surface anti gen; HCV = hepatitis C virus ; 
HCVAb  = hepatitis C virus antibod y; HIVAb  = human immunodeficiency virus  antibody; RBC = red blood cell; 
RNA  = ribonucleic acid ; WBC = white blood cell    
 
a Urine  microscopy  will be conducted  only as a reflex  test following  abnormal  urinalysis  results.  
 
  
DocuSign Envelope ID: 5DE41D60-1EAD-402F-B856-9D1227B1E269
Edgewise Therapeutics   Protocol EDG -5506 -002 
EDG -5506   Version 6.0 
 
CONFIDENTIAL AND PROPRIETARY  Page 48 of 54  Appendix D Abbreviations   
Abbreviation  Definition/Explanation  
µM microm olar 
ACTIVLIM  activity limitations for patients with upper and/or lower limb impairments  
AE adverse event  
ALT  alanine aminotransferase  
AST  aspartate aminotransfer ase 
AUC0 -24 Area under the plasma concentration -time curve from time zero to 24 hours  
BMD  Becker muscular dystrophy  
BMI  body mass index  
BP blood pressure  
CBC  complete blood count  
CFR  Code of Federal Regulations  
CK creatine kinase  
CRF  case report form  
CSP clinical study protocol  
CSR  clinical study report  
C-SSRS  Columbia Suicide Severity Rating Scale  
CYP  cytochrome P450  
D day 
DAIDS  Division of Allergy and Infectious Diseases  
DMC  Data Monitoring Committee  
DMD  Duchenne muscular dystrophy  
DXA  dual-energy X -ray absorptiometry  
eCRF  electronic case report form  
eGFR  estimated glome rular filtration rate  
ET end of treatment  
ECG  electrocardiogram  
FEV 1 forced expi[INVESTIGATOR_3741] 1 second  
FVC  forced vital capacity  
FVC%  forced vital capacity percentage  
GCP  Good Clinical Practice  
GLDH  glutamate dehydrogenase  
GGT  gamma -glutamyl transferase  
DocuSign Envelope ID: 5DE41D60-1EAD-402F-B856-9D1227B1E269
Edgewise Therapeutics   Protocol EDG -5506 -002 
EDG -5506   Version 6.0 
 
CONFIDENTIAL AND PROPRIETARY  Page 49 of 54  Abbreviation  Definition/Explanation  
HBsAg  hepatitis B surface antigen  
HDPE  high density polyethylene  
HIPAA  Health Insurance Portability and Accountability Act  
HCV  hepatitis C virus  
HCVAb hepatitis C virus antibody  
HIV human immunodeficiency virus  
HIVAb  human immunodeficiency virus antibody  
IB Investigator’s Brochure  
IC50 half-maximal inhibitory concentration  
ICF informed consent form  
ICH International Council for Harmonisation  
IEC Independent Ethics Committee  
INR international normalized ratio  
IRB Institutional Review Board  
IRT interactive response technology  
kg kilogram  
LVEF  left ventricular ejection fraction  
m meter  
MAD  multiple ascending dose  
MedDRA  Medical Dictionary for Regulatory Activities  
mg milligrams  
min minute  
mL milliliter  
ng nanogram  
NHANES III  Third National Health and Nutrition Examination Survey  
NSAA  North Star Ambulatory Assessment  
NSAD  North Star Assessment for Limb Girdle Type Muscular Dystrophies  
NT-proBNP  N-terminal prohormone brain natriuretic  peptide  
NYHA  [LOCATION_001] Heart Association  
PCR  polymerase chain reaction  
PK pharmacokinetic(s)  
PR PR interval  
PROMIS -57 Patient -Reported Outcomes Measurement Information System – 57 item s  
DocuSign Envelope ID: 5DE41D60-1EAD-402F-B856-9D1227B1E269
Edgewise Therapeutics   Protocol EDG -5506 -002 
EDG -5506   Version 6.0 
 
CONFIDENTIAL AND PROPRIETARY  Page 50 of 54  Abbreviation  Definition/Explanation  
PT prothrombin time  
QRS  QRS complex  
QT QT interval  
QTc QT interval corrected  
RBC red blood cell  
RNA  ribonucleic acid  
SAE  serious adverse event  
SAD  single ascending dose  
SAP Statistical Analysis Plan  
SoA Schedule of Activities  
TEAE  treatment -emergent adverse event  
U/L units per liter  
ULN  upper limit of normal  
WBC  white blood cell  
 
  
DocuSign Envelope ID: 5DE41D60-1EAD-402F-B856-9D1227B1E269
Edgewise Therapeutics   Protocol EDG -5506 -002 
EDG -5506   Version 6.0 
 
CONFIDENTIAL AND PROPRIETARY  Page 51 of 54  Appendix E Protocol Amendment History  
The Protocol Amendment Summary of Changes Table for the current amendment is located 
directly before the table of contents (TOC).  
Amendment 4 (Version 5.0): 11 October 2022  
Section # and Name  [CONTACT_9353] 1.[ADDRESS_1001124] been made to the text (addition of detail 
and for clarification), consistent with standard practices, which do not 
significantly change the intent of the document.  
Amendment 3 (Version 4.0): 02 June 2022  
Section # and Name  [CONTACT_9353] 1.1: Intervention 
Groups and Duration  
 
Section 4.[ADDRESS_1001125] been made to the text (addition of detail 
and for clarification), consistent with standard pra ctices, which do not 
significantly change the intent of the document.  
 
 
 
 
DocuSign Envelope ID: 5DE41D60-1EAD-402F-B856-9D1227B1E269

Edgewise Therapeutics   Protocol EDG -5506 -002 
EDG -5506   Version 6.0 
 
CONFIDENTIAL AND PROPRIETARY  Page 52 of 54  Amendment 2 (Version 3.0): 03 February 2022  
Section # and Name  [CONTACT_9353] 1.1: Intervention 
Groups and Duration  
 
Section 4.3  
Justification for Dose 
 
Section 6.1  
Study Intervention 
Administered  Dose will be escalated from 
10 mg to 15 mg starting at 
Visit 8.  Based on additional PK data from the 
Phase 1 Study EDG -5506 -001, exposures 
at steady state with a daily dose of 15 mg 
in this study are anticipated to be similar to  
well-tolerated exposures observed in the 
Study EDG -5506 -001 in participants with 
BMD or healthy adult volunteers , which 
supports an increase from 10 mg to 1 5 mg 
QD at Visit 8 (after 2 months at 10 mg).  
Section 6.[ADDRESS_1001126] ivities  
 
Section [IP_ADDRESS]  
Pedometer  
 Add pedometer data 
collection during 
telemedicine video calls 
starting at Visit [ADDRESS_1001127] been made to the text (addition of detail 
and for clarification), consistent with standard practices, which do not 
significantly change the intent of the document.  
  
DocuSign Envelope ID: 5DE41D60-1EAD-402F-B856-9D1227B1E269

Edgewise Therapeutics   Protocol EDG -5506 -002 
EDG -5506   Version 6.0 
 
CONFIDENTIAL AND PROPRIETARY  Page 53 of 54  Amendment 1 (Version 2.0) : 20 December 2021  
Section # and Name  [CONTACT_9353] 1.3: Schedule of 
Activities  The PK collection and biomarker 
labs have been removed from 
visits : V5, V7, V9  To align with site visit s 
Height added at V1 To allow BMI  calculation and forced 
vital capacity percentage  
Spi[INVESTIGATOR_732699] V2 to V1  To use for eligibility  
Treatment period has been 
extended from 3 months to 12 
months  To support long -term data collection of 
safety and biomarker data with EDG -
5506  
Section  4.2: Scientifi c 
Rationale for Study 
Design  
Section  4.3: Justification 
for Dose  
Section 6.1: Study 
Intervention 
Administered  Dose  has been updated from 
loading dose of 10 mg  and 
maintenance dose of 7.5 mg to 
dose of 10 mg throughout open -
label treatment period  Based on emerging data from the 
EDG -5506 -001 study , the half -life of 
EDG -5506 is sho rter in adults with 
BMD, approximately 7 day s compared 
with 18 days in healthy volunteers . 
Steady -state concentrations at a dose 
of 10 mg are anticipated to be less than 
those previously evaluated at 20 mg 
once daily for 14 days in EDG -5506 -
001 in particip ants with BMD .  
Section 5.1, 5.2: 
Inclusion /Exclusion  
Criteria  Updated Sex and Contraceptive 
Requirements to include sperm 
donati on restrictions  To provide more robust  guidance 
around  contraceptive requirements  
Removed reference to Day [ADDRESS_1001128] been made to the text (addition of detail 
and for clarification), consistent with standard practices, which do not 
significantly change the intent of the document.  
  
DocuSign Envelope ID: 5DE41D60-1EAD-402F-B856-9D1227B1E269

Edgewise Therapeutics   Protocol EDG -5506 -002 
EDG -5506   Version 6.0 
 
CONFIDENTIAL AND PROPRIETARY  Page 54 of 54  11. References  
Centers for Disease  Control and  Prevention . (1994). "National Health and Nutrition Examination 
Survey (NHANES III (1988 -1994))." from 
https://wwwn.cdc.gov/nchs/nhanes/nhanes3/Default.aspx?CDC_AA_refVal=https%3A%2F%2F
www.cdc.gov%2Fnchs%2Fnhanes%2Fnh3data.htm . 
Fukada, S., D. Morikawa, Y. Yamamoto, T. Yoshida, N. Sumie, et al. (2010). Genetic 
background affects properties of satellite cells and mdx phenotypes. Am J Pathol, 176(5): 2414 -
2424.  
Jacobs, M., M. K. James, L. P. Lowes, L. N. Alfano, M. Eagle, et al.  (2021). Assessing 
Dysferlinopat hy Patients Over Three Years With A New Motor Scale. Ann Neurol.  
Kornegay, J. N. (2017). The golden retriever model of Duchenne muscular dystrophy. Skelet 
Muscle, 7(1): 9.  
Mazzone, E. S., S. Messina, G. Vasco, M. Main, M. Eagle, et al.  (2009). Reliability of the North 
Star Ambulatory Assessment in a multicentric setting. Neuromuscul Disord, 19(7): 458 -461. 
Schomaker, S., D. Potter, R. Warner, J. Larkindale, N. King, et al.  (2020). Serum glutamate 
dehydrogenase activity enables early detection of liver injur y in subjects with underlying muscle 
impairments. PLoS One, 15(5): e0229753.  
Webster, C., L. Silberstein, A. P. Hays and H. M. Blau (1988). Fast muscle fibers are 
preferentially affected in Duchenne muscular dystrophy. Cell, 52(4): 503 -513. 
 
DocuSign Envelope ID: 5DE41D60-1EAD-402F-B856-9D1227B1E269